PharmaNet’s Bioanalytical Laboratory Recognized by the Standards Council of Canada for Good Laboratory Practice Compliance
News Jun 29, 2011
PharmaNet Development Group, Inc., has announced that its bioanalytical laboratory in Quebec City, Canada, has received formal recognition from the Standards Council of Canada (SCC) for its compliance with the Organization for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice (GLP).
“After an in-depth review by a four-person inspection team, the Standards Council of Canada awarded us with official recognition of GLP compliance, acknowledging the premier level of quality and compliance maintained in our laboratory,” said Tony Jones, Executive Director, Quality Assurance and Compliance.
Mr. Jones continued, “We have a long track record of successful inspections from global regulatory bodies, including a re-certification from Brazil's ANVISA just prior to the SCC inspection. This OECD GLP recognition consolidates our position as the partner of choice for companies seeking assured international registration of their products.”
The final guidance describing the program was announced by Health Canada in April 2010. Thirty-four countries in North America, Europe and Asia constitute the OECD, an inter-governmental organization that pursues, among many other policies, the international harmonization of test methods and good laboratory practices.
Upholding the principles of GLP ensures that a laboratory’s quality system and management controls are consistent and reliable, which is essential for producing high quality and valid test data.
PharmaNet’s laboratories offer complete bioanalytical services for small and large molecules across the continuum of drug development.
The company’s other laboratory in Princeton, NJ, is also GLP-compliant. Together the labs offer an extensive method development and validation services, with more than 1000 validated assays and rapid sample handling capabilities.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE